LYMErix®
Antigen = 30 µg of OspA adsorbed on Alum
Injections at 0, 1, 12 Mo
Efficacy trial:
- safety/reactogenicity OK
- 78 % efficacy against disease
- 100 % efficacy against asymptomatic infection
Protects against Borrelia burgdorferi infection
Launched in USA in January 1999
Discontinued in February 2002 because of poor sales...